Cesca Therapeutics Inc. announced that it has received $0.8 million in funding
January 28, 2019
Share
Cesca Therapeutics Inc. (NasdaqCM:KOOL) announced that it has entered into a securities purchase agreement with accredited investor, Orbrex (USA) Co. Limited for private placement of unsecured convertible promissory notes for gross proceeds of $800,000 on January 29, 2019. The note carries a fixed coupon of 24% per annum and would mature on eighteen months from the date of closing. The interest is payable quarterly in arrears on March 31, June 30, September 30, and December 31 of each year. The notes are convertible into common stock of the company, at a conversion price equal to the lower of $0.18 per share or 90% of the closing sale price of the company’s common stock on the date of conversion. If the shareholder approval is not obtained in the next annual meeting of the shareholder, then the maturity date will accelerate to the date that is fourteen days after the next annual meeting. The notes may be prepaid without penalty at any time after the notes become convertible. The company has issued securities pursuant to exemption provided under Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
THERMOGENESIS HOLDINGS, INC. 
